Andrew Mignatti, Co-Founder and CEO of careviso, looks at the possibility of the United States (US) adopting international reference pricing and asks if it is possible to lower drug costs without undermining innovation.  Discussion around international reference pricing (IRP) is intensifying as policymakers search for ways to address persistently high prescription drug costs in the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!